109. 非典型溶血性尿毒症症候群 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 114 / 薬物数 : 36 - (DrugBank : 7) / 標的遺伝子数 : 3 - 標的パスウェイ数 : 11
薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。
ALN-62643
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
2019 Phase 2 EUCTR2018-004382-13-IT Italy;
ALN-CC5
Alnylam Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2017-001082-24-SE Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
2017 Phase 2 EUCTR2017-001082-24-LV Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
2017 Phase 2 EUCTR2017-001082-24-LT Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
2017 Phase 2 EUCTR2017-001082-24-EE Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
2019 Phase 2 EUCTR2018-004382-13-IT Italy;
ALXN1210
ALEXION PHARMACEUTICALS INCORPORATED
2017 Phase 3 EUCTR2016-002027-29-IT Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
Alexion Pharmaceuticals Incorporated
2019 Phase 3 EUCTR2016-002499-29-FR Austria;Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-SE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-IT Austria;Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-GB Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-ES Spain;United States;
2017 Phase 3 EUCTR2016-002499-29-DE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-BE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-AT Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002027-29-SE Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002027-29-ES Austria;Spain;United States;
2017 Phase 3 EUCTR2016-002027-29-DE Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002027-29-BE Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002027-29-GB Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002027-29-AT Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2016-002027-29-CZ Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
Anti-C5 antibody
ALEXION PHARMACEUTICALS, INC.
2013 Phase 2 EUCTR2010-020326-18-FR Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-020326-18-BE Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-020310-28-GB Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-020310-28-ES Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2011 - EUCTR2010-020326-18-NL Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 - EUCTR2010-020310-28-NL Austria;Belgium;Italy;Netherlands;Spain;United Kingdom;
2011 - EUCTR2010-020310-28-DE Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 - EUCTR2010-020310-28-BE Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2010 - EUCTR2010-020326-18-GB Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2010 - EUCTR2010-020326-18-DE Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2010 - EUCTR2010-020310-28-AT Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-006955-28-GB Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006954-17-GB Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006953-41-GB Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006953-41-AT Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006952-23-GB Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006952-23-FR Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-SE Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-NL Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-DE Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-AT Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-SE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-NL Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-FR Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-DE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-AT Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-SE Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-NL Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-DE Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-SE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-NL Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-DE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-AT Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
- Phase 2 EUCTR2010-020310-28-FR Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
C5 inh MAb, SKY59, RO/CH7092230
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 3 EUCTR2020-002475-35-IT Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002437-15-IT Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-002475-35-PL Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002475-35-FR Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002475-35-DE Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-002475-35-BE Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
F.Hoffmann-La Roche Ltd
2022 Phase 3 EUCTR2020-002437-15-HU Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 EUCTR2020-002437-15-PL Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 EUCTR2020-002437-15-FR Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
- Phase 3 EUCTR2020-002437-15-BE Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-002437-15-ES Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
CCX168
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
2015 Phase 2 EUCTR2014-004261-24-IT Italy;
Mario Negri Institute for Pharmacological Research
2015 Phase 2 NCT02464891 Italy;
COVERSIN
Akari Therapeutics Plc
2019 Phase 3 EUCTR2016-004129-18-LT Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
Cemdisiran
Alnylam Pharmaceuticals
2017 Phase 2 NCT03303313 Bosnia and Herzegovina;Canada;Estonia;Georgia;Latvia;Lithuania;Macedonia, The Former Yugoslav Republic of;Moldova, Republic of;Serbia;Sweden;
Alnylam Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2017-001082-24-SE Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
2017 Phase 2 EUCTR2017-001082-24-LV Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
2017 Phase 2 EUCTR2017-001082-24-LT Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
2017 Phase 2 EUCTR2017-001082-24-EE Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
2019 Phase 2 EUCTR2018-004382-13-IT Italy;
Mario Negri Institute for Pharmacological Research
2021 Phase 2 NCT03999840 Italy;
Crovalimab
Camelia Sima
2021 Phase 3 JPRN-jRCT2031210061 BELGIUM;BRAZIL;CANADA;CHINA;FRANCE;GERMANY;Japan;MEXICO;POLAND;UNITED STATES;
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 3 EUCTR2020-002475-35-IT Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-002475-35-PL Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002475-35-FR Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002475-35-DE Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-002475-35-BE Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
Hoffmann-La Roche
2021 Phase 3 NCT04958265 Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 NCT04861259 Belgium;Brazil;Canada;China;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Peru;Poland;South Africa;Spain;Turkey;United States;
Mona D. Shah
2021 Phase 3 JPRN-jRCT2041210086 Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
Eculizumab
ALEXION PHARMACEUTICALS
2011 - EUCTR2010-020310-28-IT Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-006955-28-IT Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-IT Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-IT Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-IT Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
ALEXION PHARMACEUTICALS INCORPORATED
- Phase 4 EUCTR2015-003135-35-IT Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Norway;Poland;Russian Federation;Spain;United Arab Emirates;United Kingdom;United States;
ALEXION PHARMACEUTICALS, INC.
2013 Phase 2 EUCTR2010-020326-18-FR Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-020326-18-BE Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-020310-28-GB Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-020310-28-ES Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2011 - EUCTR2010-020326-18-NL Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 - EUCTR2010-020310-28-NL Austria;Belgium;Italy;Netherlands;Spain;United Kingdom;
2011 - EUCTR2010-020310-28-DE Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 - EUCTR2010-020310-28-BE Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2010 - EUCTR2010-020326-18-GB Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2010 - EUCTR2010-020326-18-DE Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2010 - EUCTR2010-020310-28-AT Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-006955-28-GB Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006954-17-GB Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006953-41-GB Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006953-41-AT Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006952-23-GB Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006952-23-FR Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-SE Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-NL Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-DE Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-AT Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-SE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-NL Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-FR Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-DE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-AT Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-SE Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-NL Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-DE Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-SE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-NL Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-DE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-AT Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
- Phase 2 EUCTR2010-020310-28-FR Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Alexion Pharmaceuticals
2015 - NCT02614898 Australia;Germany;United Kingdom;United States;
2012 Phase 2 NCT01757431 Japan;
2010 Phase 2 NCT01194973 Belgium;France;Germany;Italy;Spain;United Kingdom;United States;
2010 Phase 2 NCT01193348 Australia;Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2009 Phase 2 NCT00844844 Austria;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2009 Phase 2 NCT00844545 Austria;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2009 Phase 2 NCT00844428 Austria;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2009 Phase 2 NCT00838513 Austria;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
Children's Hospital Medical Center, Cincinnati
2018 Phase 2 NCT03518203 United States;
Nantes University Hospital
2015 Phase 4 NCT02574403 France;
Newcastle Upon Tyne Hospitals NHS Foundation Trust
2018 Phase 2 EUCTR2017-003916-37-GB United Kingdom;
Elizaria®
AO GENERIUM
2019 - NCT04749810 Russian Federation;
Fc- and CDR-modified humanised monoclonal antibody against C5
ALEXION PHARMACEUTICALS INCORPORATED
2017 Phase 3 EUCTR2016-002027-29-IT Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
Alexion Pharmaceuticals Incorporated
2019 Phase 3 EUCTR2016-002499-29-FR Austria;Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-SE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-IT Austria;Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-GB Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-ES Spain;United States;
2017 Phase 3 EUCTR2016-002499-29-DE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-BE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-AT Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002027-29-SE Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002027-29-DE Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002027-29-BE Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002027-29-AT Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2016-002027-29-CZ Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
IgG2/4?
Newcastle Upon Tyne Hospitals NHS Foundation Trust
2018 Phase 2 EUCTR2017-003916-37-GB United Kingdom;
Iptacopan
Novartis Pharma AG
2021 Phase 3 EUCTR2020-005186-13-SI Austria;Brazil;China;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Slovenia;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2020-005186-13-AT Austria;Brazil;China;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Taiwan;United Kingdom;United States;
Novartis Pharmaceuticals
2022 Phase 3 NCT04889430 Austria;Greece;Japan;Korea, Republic of;Slovenia;Taiwan;
OMS00620646, OMS620646, MASP-2 Antibody
Omeros Corporation
2018 Phase 3 EUCTR2017-002057-11-PL Lithuania;Poland;Taiwan;United States;
2017 Phase 3 EUCTR2017-002057-11-LT Lithuania;Poland;Taiwan;United States;
OMS721
Omeros Corporation
2017 Phase 3 NCT03205995 United States;
OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody
Omeros Corporation
2014 Phase 2 EUCTR2014-001032-11-PL Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
2014 Phase 2 EUCTR2014-001032-11-LT Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
2014 Phase 2 EUCTR2014-001032-11-BE Belarus;Belgium;Bulgaria;Germany;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody
Omeros Corporation
2014 Phase 2 EUCTR2014-001032-11-PL Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
2014 Phase 2 EUCTR2014-001032-11-LT Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
OMS721 Drug Product 185 mg/mL
Omeros Corporation
2018 Phase 3 EUCTR2017-002057-11-PL Lithuania;Poland;Taiwan;United States;
2017 Phase 3 EUCTR2017-002057-11-LT Lithuania;Poland;Taiwan;United States;
RO7112689/F03-01
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 3 EUCTR2020-002437-15-IT Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
F.Hoffmann-La Roche Ltd
2022 Phase 3 EUCTR2020-002437-15-HU Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 EUCTR2020-002437-15-PL Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 EUCTR2020-002437-15-FR Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
- Phase 3 EUCTR2020-002437-15-BE Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-002437-15-ES Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
RO7112689/F03-10
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 3 EUCTR2020-002475-35-IT Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002437-15-IT Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-002475-35-PL Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002475-35-FR Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002475-35-DE Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-002475-35-BE Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
F.Hoffmann-La Roche Ltd
2022 Phase 3 EUCTR2020-002437-15-HU Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 EUCTR2020-002437-15-PL Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 EUCTR2020-002437-15-FR Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
- Phase 3 EUCTR2020-002437-15-BE Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-002437-15-ES Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
RVA576
Akari Therapeutics Plc
2019 Phase 3 EUCTR2016-004129-18-LT Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
2018 Phase 3 EUCTR2016-004129-18-NL Argentina;Lithuania;Netherlands;Poland;United Kingdom;
2017 Phase 3 EUCTR2016-004129-18-GB Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
2017 Phase 2 EUCTR2017-000064-15-GB United Kingdom;
RVA576 (COVERSIN)
Akari Therapeutics Plc
2017 Phase 3 EUCTR2016-004129-18-PL Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
RVA576 (Coversin)
Akari Therapeutics Plc
2017 Phase 3 EUCTR2016-004129-18-PL Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
Ravulizumab
Alexion Pharmaceuticals
2017 Phase 3 NCT03131219 Belgium;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
2017 Phase 3 NCT02949128 Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Taiwan;United Kingdom;United States;
Alexion Pharmaceuticals Incorporated
2017 Phase 3 EUCTR2016-002499-29-SE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-GB Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-DE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-BE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-AT Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML)
ALEXION PHARMACEUTICALS INCORPORATED
- Phase 4 EUCTR2015-003135-35-IT Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Norway;Poland;Russian Federation;Spain;United Arab Emirates;United Kingdom;United States;
SOLIRIS 300 mg concentrado para solución para perfusión
ALEXION PHARMACEUTICALS, INC.
2011 Phase 2 EUCTR2010-020326-18-ES Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-006955-28-ES Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-ES Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-ES Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Solaris
Newcastle Upon Tyne Hospitals NHS Foundation Trust
2018 Phase 2 EUCTR2017-003916-37-GB United Kingdom;
LNP023 HYDROCHLORIDE SALT
Novartis Pharma AG
2021 Phase 3 EUCTR2020-005186-13-SI Austria;Brazil;China;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Slovenia;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2020-005186-13-AT Austria;Brazil;China;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Taiwan;United Kingdom;United States;
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
2019 Phase 2 EUCTR2018-004382-13-IT Italy;
ALN-CC5
Alnylam Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2017-001082-24-SE Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
2017 Phase 2 EUCTR2017-001082-24-LV Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
2017 Phase 2 EUCTR2017-001082-24-LT Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
2017 Phase 2 EUCTR2017-001082-24-EE Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
2019 Phase 2 EUCTR2018-004382-13-IT Italy;
ALXN1210
ALEXION PHARMACEUTICALS INCORPORATED
2017 Phase 3 EUCTR2016-002027-29-IT Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
Alexion Pharmaceuticals Incorporated
2019 Phase 3 EUCTR2016-002499-29-FR Austria;Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-SE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-IT Austria;Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-GB Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-ES Spain;United States;
2017 Phase 3 EUCTR2016-002499-29-DE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-BE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-AT Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002027-29-SE Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002027-29-ES Austria;Spain;United States;
2017 Phase 3 EUCTR2016-002027-29-DE Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002027-29-BE Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002027-29-GB Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002027-29-AT Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2016-002027-29-CZ Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
Anti-C5 antibody
ALEXION PHARMACEUTICALS, INC.
2013 Phase 2 EUCTR2010-020326-18-FR Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-020326-18-BE Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-020310-28-GB Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-020310-28-ES Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2011 - EUCTR2010-020326-18-NL Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 - EUCTR2010-020310-28-NL Austria;Belgium;Italy;Netherlands;Spain;United Kingdom;
2011 - EUCTR2010-020310-28-DE Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 - EUCTR2010-020310-28-BE Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2010 - EUCTR2010-020326-18-GB Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2010 - EUCTR2010-020326-18-DE Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2010 - EUCTR2010-020310-28-AT Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-006955-28-GB Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006954-17-GB Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006953-41-GB Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006953-41-AT Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006952-23-GB Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006952-23-FR Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-SE Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-NL Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-DE Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-AT Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-SE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-NL Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-FR Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-DE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-AT Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-SE Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-NL Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-DE Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-SE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-NL Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-DE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-AT Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
- Phase 2 EUCTR2010-020310-28-FR Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
C5 inh MAb, SKY59, RO/CH7092230
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 3 EUCTR2020-002475-35-IT Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002437-15-IT Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-002475-35-PL Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002475-35-FR Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002475-35-DE Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-002475-35-BE Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
F.Hoffmann-La Roche Ltd
2022 Phase 3 EUCTR2020-002437-15-HU Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 EUCTR2020-002437-15-PL Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 EUCTR2020-002437-15-FR Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
- Phase 3 EUCTR2020-002437-15-BE Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-002437-15-ES Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
CCX168
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
2015 Phase 2 EUCTR2014-004261-24-IT Italy;
Mario Negri Institute for Pharmacological Research
2015 Phase 2 NCT02464891 Italy;
COVERSIN
Akari Therapeutics Plc
2019 Phase 3 EUCTR2016-004129-18-LT Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
Cemdisiran
Alnylam Pharmaceuticals
2017 Phase 2 NCT03303313 Bosnia and Herzegovina;Canada;Estonia;Georgia;Latvia;Lithuania;Macedonia, The Former Yugoslav Republic of;Moldova, Republic of;Serbia;Sweden;
Alnylam Pharmaceuticals, Inc.
2017 Phase 2 EUCTR2017-001082-24-SE Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
2017 Phase 2 EUCTR2017-001082-24-LV Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
2017 Phase 2 EUCTR2017-001082-24-LT Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
2017 Phase 2 EUCTR2017-001082-24-EE Albania;Bosnia and Herzegovina;Canada;Estonia;Georgia;India;Latvia;Lithuania;Macedonia, the former Yugoslav Republic of;Moldova, Republic of;Romania;Serbia;Sweden;
IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
2019 Phase 2 EUCTR2018-004382-13-IT Italy;
Mario Negri Institute for Pharmacological Research
2021 Phase 2 NCT03999840 Italy;
Crovalimab
Camelia Sima
2021 Phase 3 JPRN-jRCT2031210061 BELGIUM;BRAZIL;CANADA;CHINA;FRANCE;GERMANY;Japan;MEXICO;POLAND;UNITED STATES;
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 3 EUCTR2020-002475-35-IT Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-002475-35-PL Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002475-35-FR Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002475-35-DE Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-002475-35-BE Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
Hoffmann-La Roche
2021 Phase 3 NCT04958265 Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 NCT04861259 Belgium;Brazil;Canada;China;France;Germany;Hungary;Israel;Italy;Japan;Mexico;Peru;Poland;South Africa;Spain;Turkey;United States;
Mona D. Shah
2021 Phase 3 JPRN-jRCT2041210086 Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
Eculizumab
ALEXION PHARMACEUTICALS
2011 - EUCTR2010-020310-28-IT Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-006955-28-IT Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-IT Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-IT Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-IT Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
ALEXION PHARMACEUTICALS INCORPORATED
- Phase 4 EUCTR2015-003135-35-IT Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Norway;Poland;Russian Federation;Spain;United Arab Emirates;United Kingdom;United States;
ALEXION PHARMACEUTICALS, INC.
2013 Phase 2 EUCTR2010-020326-18-FR Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-020326-18-BE Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-020310-28-GB Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 Phase 2 EUCTR2010-020310-28-ES Australia;Austria;Belgium;Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2011 - EUCTR2010-020326-18-NL Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 - EUCTR2010-020310-28-NL Austria;Belgium;Italy;Netherlands;Spain;United Kingdom;
2011 - EUCTR2010-020310-28-DE Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2011 - EUCTR2010-020310-28-BE Australia;Austria;Belgium;Canada;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
2010 - EUCTR2010-020326-18-GB Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2010 - EUCTR2010-020326-18-DE Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2010 - EUCTR2010-020310-28-AT Austria;Belgium;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 Phase 2 EUCTR2008-006955-28-GB Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006954-17-GB Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006953-41-GB Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006953-41-AT Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006952-23-GB Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 Phase 2 EUCTR2008-006952-23-FR Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-SE Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-NL Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-DE Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006955-28-AT Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-SE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-NL Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-FR Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-DE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-AT Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-SE Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-NL Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006953-41-DE Austria;Germany;Italy;Netherlands;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-SE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-NL Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-DE Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-AT Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
- Phase 2 EUCTR2010-020310-28-FR Austria;Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
Alexion Pharmaceuticals
2015 - NCT02614898 Australia;Germany;United Kingdom;United States;
2012 Phase 2 NCT01757431 Japan;
2010 Phase 2 NCT01194973 Belgium;France;Germany;Italy;Spain;United Kingdom;United States;
2010 Phase 2 NCT01193348 Australia;Belgium;Canada;France;Germany;Italy;Netherlands;United Kingdom;United States;
2009 Phase 2 NCT00844844 Austria;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2009 Phase 2 NCT00844545 Austria;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2009 Phase 2 NCT00844428 Austria;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
2009 Phase 2 NCT00838513 Austria;Canada;France;Germany;Italy;Netherlands;Spain;Sweden;Switzerland;United Kingdom;United States;
Children's Hospital Medical Center, Cincinnati
2018 Phase 2 NCT03518203 United States;
Nantes University Hospital
2015 Phase 4 NCT02574403 France;
Newcastle Upon Tyne Hospitals NHS Foundation Trust
2018 Phase 2 EUCTR2017-003916-37-GB United Kingdom;
Elizaria®
AO GENERIUM
2019 - NCT04749810 Russian Federation;
Fc- and CDR-modified humanised monoclonal antibody against C5
ALEXION PHARMACEUTICALS INCORPORATED
2017 Phase 3 EUCTR2016-002027-29-IT Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
Alexion Pharmaceuticals Incorporated
2019 Phase 3 EUCTR2016-002499-29-FR Austria;Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-SE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-IT Austria;Belgium;France;Germany;Italy;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-GB Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-ES Spain;United States;
2017 Phase 3 EUCTR2016-002499-29-DE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-BE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-AT Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002027-29-SE Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002027-29-DE Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002027-29-BE Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
2016 Phase 3 EUCTR2016-002027-29-AT Australia;Austria;Belgium;Czech Republic;France;Germany;Italy;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
- Phase 3 EUCTR2016-002027-29-CZ Australia;Austria;Belgium;Czech Republic;France;Germany;Japan;Korea, Republic of;Spain;Sweden;United Kingdom;United States;
IgG2/4?
Newcastle Upon Tyne Hospitals NHS Foundation Trust
2018 Phase 2 EUCTR2017-003916-37-GB United Kingdom;
Iptacopan
Novartis Pharma AG
2021 Phase 3 EUCTR2020-005186-13-SI Austria;Brazil;China;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Slovenia;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2020-005186-13-AT Austria;Brazil;China;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Taiwan;United Kingdom;United States;
Novartis Pharmaceuticals
2022 Phase 3 NCT04889430 Austria;Greece;Japan;Korea, Republic of;Slovenia;Taiwan;
OMS00620646, OMS620646, MASP-2 Antibody
Omeros Corporation
2018 Phase 3 EUCTR2017-002057-11-PL Lithuania;Poland;Taiwan;United States;
2017 Phase 3 EUCTR2017-002057-11-LT Lithuania;Poland;Taiwan;United States;
OMS721
Omeros Corporation
2017 Phase 3 NCT03205995 United States;
OMS721 100 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody
Omeros Corporation
2014 Phase 2 EUCTR2014-001032-11-PL Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
2014 Phase 2 EUCTR2014-001032-11-LT Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
2014 Phase 2 EUCTR2014-001032-11-BE Belarus;Belgium;Bulgaria;Germany;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Switzerland;Taiwan;Thailand;Turkey;United Kingdom;United States;
OMS721 185 mg/ml Injection solution, OMS00620646, OMS620646, MASP-2 Antibody
Omeros Corporation
2014 Phase 2 EUCTR2014-001032-11-PL Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
2014 Phase 2 EUCTR2014-001032-11-LT Belgium;Bulgaria;Hong Kong;Italy;Lithuania;Malaysia;New Zealand;Poland;Singapore;Taiwan;Thailand;United States;
OMS721 Drug Product 185 mg/mL
Omeros Corporation
2018 Phase 3 EUCTR2017-002057-11-PL Lithuania;Poland;Taiwan;United States;
2017 Phase 3 EUCTR2017-002057-11-LT Lithuania;Poland;Taiwan;United States;
RO7112689/F03-01
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 3 EUCTR2020-002437-15-IT Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
F.Hoffmann-La Roche Ltd
2022 Phase 3 EUCTR2020-002437-15-HU Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 EUCTR2020-002437-15-PL Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 EUCTR2020-002437-15-FR Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
- Phase 3 EUCTR2020-002437-15-BE Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-002437-15-ES Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
RO7112689/F03-10
F. HOFFMANN - LA ROCHE LTD.
2021 Phase 3 EUCTR2020-002475-35-IT Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002437-15-IT Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-002475-35-PL Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002475-35-FR Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
2021 Phase 3 EUCTR2020-002475-35-DE Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
- Phase 3 EUCTR2020-002475-35-BE Australia;Belgium;Brazil;Canada;China;Czechia;France;Germany;Hungary;Israel;Italy;Korea, Republic of;Luxembourg;Mexico;Peru;Poland;South Africa;Spain;Turkey;United Kingdom;United States;
F.Hoffmann-La Roche Ltd
2022 Phase 3 EUCTR2020-002437-15-HU Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 EUCTR2020-002437-15-PL Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
2021 Phase 3 EUCTR2020-002437-15-FR Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
- Phase 3 EUCTR2020-002437-15-BE Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
Roche Farma S. A. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
2021 Phase 3 EUCTR2020-002437-15-ES Belgium;Brazil;Canada;China;France;Hungary;Israel;Italy;Japan;Poland;South Africa;Spain;United States;
RVA576
Akari Therapeutics Plc
2019 Phase 3 EUCTR2016-004129-18-LT Argentina;France;Germany;India;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
2018 Phase 3 EUCTR2016-004129-18-NL Argentina;Lithuania;Netherlands;Poland;United Kingdom;
2017 Phase 3 EUCTR2016-004129-18-GB Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
2017 Phase 2 EUCTR2017-000064-15-GB United Kingdom;
RVA576 (COVERSIN)
Akari Therapeutics Plc
2017 Phase 3 EUCTR2016-004129-18-PL Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
RVA576 (Coversin)
Akari Therapeutics Plc
2017 Phase 3 EUCTR2016-004129-18-PL Argentina;France;Germany;Kazakhstan;Lithuania;Netherlands;Poland;Sri Lanka;United Kingdom;
Ravulizumab
Alexion Pharmaceuticals
2017 Phase 3 NCT03131219 Belgium;Germany;Italy;Japan;Korea, Republic of;Spain;United Kingdom;United States;
2017 Phase 3 NCT02949128 Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Taiwan;United Kingdom;United States;
Alexion Pharmaceuticals Incorporated
2017 Phase 3 EUCTR2016-002499-29-SE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-GB Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-DE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-BE Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
2017 Phase 3 EUCTR2016-002499-29-AT Australia;Austria;Belgium;Canada;France;Germany;Italy;Japan;Korea, Republic of;Russian Federation;Spain;Sweden;Taiwan;United Kingdom;United States;
SOLIRIS - 300 MG CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO 1 FLACONCINO (VETRO) 30 ML (10 MG/ML)
ALEXION PHARMACEUTICALS INCORPORATED
- Phase 4 EUCTR2015-003135-35-IT Australia;Belgium;Canada;Czech Republic;Germany;Israel;Italy;Norway;Poland;Russian Federation;Spain;United Arab Emirates;United Kingdom;United States;
SOLIRIS 300 mg concentrado para solución para perfusión
ALEXION PHARMACEUTICALS, INC.
2011 Phase 2 EUCTR2010-020326-18-ES Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
2009 - EUCTR2008-006955-28-ES Austria;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006954-17-ES Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
2009 - EUCTR2008-006952-23-ES Austria;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;
Solaris
Newcastle Upon Tyne Hospitals NHS Foundation Trust
2018 Phase 2 EUCTR2017-003916-37-GB United Kingdom;
LNP023 HYDROCHLORIDE SALT
Novartis Pharma AG
2021 Phase 3 EUCTR2020-005186-13-SI Austria;Brazil;China;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Slovenia;Taiwan;United Kingdom;United States;
2021 Phase 3 EUCTR2020-005186-13-AT Austria;Brazil;China;Czechia;Greece;Hungary;India;Japan;Korea, Republic of;Russian Federation;Taiwan;United Kingdom;United States;